Krystal Biotech (KRYS) Company Overview

PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore's healthcare group, where he advised on transactions totaling over $500 billion in aggregate value.

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales, doubling from Q4 2023. Trading at 57x 2024 earnings, Krystal's stock appears expensive but is projected to double earnings by 2025. With imminent EU and Japanese market expansion, Krystal seems poised to outperform analyst's expectations for growth.

Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.

Initial clinical results from the KYANITE-1 study show that inhaled KB707 has promising effects in patients with lung tumors, particularly in those with advanced non-small cell lung cancer (NSCLC). The treatment achieved a 27% objective response rate (ORR) and a 73% disease control rate (DCR) as of December 6, 2024. This data supports the effectiveness of using HSV-1 based inhaled gene delivery for treating these conditions.

Krystal Biotech has shared its first clinical updates on two of its drug candidates, KB407 and KB408, which are being created to address uncommon respiratory illnesses.

The CHMP's opinion is now anticipated in the first quarter of 2025, with no major objections remaining. Krystal Biotech, Inc. still expects to launch in Germany in the second quarter of 2025. The European Medicines Agency's committee has canceled the Oral Explanation for the company's Marketing Authorization Application for B-VEC, which was set for December 6, 2024, and has requested written responses to the remaining issues.

PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company that is currently in the commercial phase, has announced that Krish S. Krishnan, the Chairman and CEO, will participate in discussions and hold meetings with investors at two upcoming conferences.

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company that is currently in the commercial stage, has announced its participation in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, the Chairman and CEO, will join a fireside chat at 1:30 pm ET and will also hold meetings with investors during the day.

KRYS exceeded expectations for both earnings and sales in the third quarter of 2024. The launch of their main drug, Vyjuvek, in the United States is seeing a positive response.